SOLO1与PAOLA-1/ENGOT-ov25的人群调整间接治疗比较:新诊断晚期BRCA突变卵巢癌维持治疗中奥拉帕利、贝伐珠单抗及两者联合的比较
在缺乏随机头对头试验的情况下,本研究对新诊断晚期BRCA突变卵巢癌患者进行了人群调整间接治疗比较(PA-ITC),整合SOLO1与PAOLA-1/ENGOT-ov25的个体患者数据。结果显示,奥拉帕利联合贝伐珠单抗较奥拉帕利单药PFS有数值改善(HR 0.71;95%CI 0.45-1.09),奥拉帕利单药、奥拉帕利联合贝伐珠单抗及贝伐珠单抗联合安慰剂均较各自对照显著改善PFS。结论支持奥拉帕利单药或联合贝伐珠单抗用于此类患者的维持治疗。
要点
- 奥拉帕利联合贝伐珠单抗较奥拉帕利单药PFS有数值改善(HR 0.71;95%CI 0.45-1.09)。
- 奥拉帕利单药较安慰剂联合贝伐珠单抗显著改善PFS(HR 0.48;95%CI 0.30-0.75)。
- 奥拉帕利联合贝伐珠单抗较安慰剂显著改善PFS(HR 0.23;95%CI 0.14-0.34)。
核心结论
- 该假设生成性PA-ITC分析结果支持奥拉帕利单药或联合贝伐珠单抗用于新诊断晚期BRCA突变卵巢癌的维持治疗。
研究设计与样本
- 采用非锚定人群调整间接治疗比较(PA-ITC),基于研究者评估的无进展生存期(PFS)数据。
- 整合SOLO1(奥拉帕利 vs 安慰剂)与PAOLA-1/ENGOT-ov25中BRCA突变患者(奥拉帕利联合贝伐珠单抗 vs 安慰剂联合贝伐珠单抗)的个体患者数据。
- 对PAOLA-1各治疗组进行加权,使关键基线特征与SOLO1队列相似,分析仅纳入基线数据完整的患者。
- 采用加权Cox回归分析估计不同维持治疗策略的相对疗效,并以加权Kaplan-Meier分析作为补充。
- SOLO1患者数据:奥拉帕利组n=254,安慰剂组n=126;PAOLA-1 BRCA突变患者数据:奥拉帕利联合贝伐珠单抗组n=151,安慰剂联合贝伐珠单抗组n=71。
主要发现
- 奥拉帕利联合贝伐珠单抗较奥拉帕利单药PFS有数值改善(HR 0.71;95%CI 0.45-1.09)。
- 奥拉帕利单药较安慰剂联合贝伐珠单抗显著改善PFS(HR 0.48;95%CI 0.30-0.75)。
- 奥拉帕利联合贝伐珠单抗较安慰剂显著改善PFS(HR 0.23;95%CI 0.14-0.34)。
- 安慰剂联合贝伐珠单抗较安慰剂显著改善PFS(HR 0.65;95%CI 0.43-0.95)。
临床怎么用
- 对于新诊断晚期BRCA突变卵巢癌患者,可考虑奥拉帕利单药或奥拉帕利联合贝伐珠单抗作为维持治疗。
- 奥拉帕利联合贝伐珠单抗较奥拉帕利单药的PFS获益为数值改善,尚未达到统计学显著,临床决策需结合患者具体情况。
局限性
- 本研究为非锚定PA-ITC,属于假设生成性分析,结果需谨慎解读。
- 分析仅纳入基线数据完整的患者,可能存在选择偏倚。
- 缺乏随机头对头试验直接比较各维持治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the absence of randomised head-to-head trials, we conducted a population-adjusted indirect treatment comparison (PA-ITC) of phase III trial data to evaluate the relative efficacy and safety of maintenance olaparib and bevacizumab alone and in combination in patients with newly diagnosed, advanced ovarian cancer and a BRCA mutation (BRCAm). METHODS: An unanchored PA-ITC was performed on investigator-assessed progression-free survival (PFS) data. Individual patient data from SOLO1 (olaparib versus placebo) and from BRCA-mutated patients in PAOLA-1/ENGOT-ov25 (olaparib plus bevacizumab versus placebo plus bevacizumab) were pooled. Each arm of PAOLA-1 was weighted so that key baseline patient characteristics were similar to the SOLO1 cohort. Analyses were performed in patients with complete baseline data. Weighted Cox regression analysis was used to estimate the comparative efficacy of different maintenance therapy strategies, supplemented by weighted Kaplan-Meier analyses. RESULTS: Data from SOLO1 patients (olaparib, n = 254; placebo, n = 126) were compared with data from BRCA-mutated PAOLA-1 patients (olaparib plus bevacizumab, n = 151; placebo plus bevacizumab, n = 71). Adding bevacizumab to olaparib was associated with a numerical improvement in PFS compared with olaparib alone (hazard ratio [HR] 0.71; 95% confidence interval [CI] 0.45-1.09). Statistically significant improvements in PFS were seen with olaparib alone versus placebo plus bevacizumab (HR 0.48; 95% CI 0.30-0.75), olaparib plus bevacizumab versus placebo (0.23; 0.14-0.34), and placebo plus bevacizumab versus placebo (0.65; 0.43-0.95). CONCLUSIONS: Results of this hypothesis-generating PA-ITC analysis support the use of maintenance olaparib alone or with bevacizumab in patients with newly diagnosed, advanced ovarian cancer and a BRCAm.
引用
- Vergote I, Ray-Coquard I, Anderson DM, et al. Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer. Eur J Cancer. 2021. PMID: 34597975. doi:10.1016/j.ejca.2021.08.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。